We also compared the surface exposure of calreticulin for primary AML cells derived from the same patients with high and low RINF expression (see Fig. 1); the exposure was then compared after culture in medium alone and in the presence of lenalidomide 0.1 μM (Fig. 4). This evidence concerns the gene CALR and acute myeloid leukemia.